|
Most Recent Releases
|
|
Date
|
Title
(click to view the full text) |
|
11/17/09
|
InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
|
|
11/5/09
|
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
|
|
11/5/09
|
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
|
|
11/4/09
|
InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
|
|
11/3/09
|
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
|
|
10/29/09
|
InterMune to Present at Oppenheimer Conference
|
|
10/29/09
|
InterMune to Release Third Quarter Financial Results on November 5
|
|
10/1/09
|
InterMune to Present at JMP Securities Conference
|
|
9/29/09
|
InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients
|
|
9/17/09
|
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
|
|
9/14/09
|
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
|
|
8/19/09
|
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
|
|
8/7/09
|
InterMune to Present at Canaccord Adams Conference
|
|
8/6/09
|
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
|
|
7/29/09
|
InterMune to Release Second Quarter Financial Results on August 6
|
|
6/3/09
|
InterMune to Present at Goldman Sachs Healthcare Conference
|
|
5/19/09
|
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
|
|
5/17/09
|
Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
|
|
5/14/09
|
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
|
|
4/30/09
|
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
|
|
4/25/09
|
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
|
|
4/24/09
|
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
|
|
4/21/09
|
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
|
|
4/21/09
|
InterMune to Release First Quarter Financial Results on April 30
|
|
4/20/09
|
InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
|
|
4/3/09
|
InterMune to Present at Canaccord Adams Hepatitis C Conference
|
|
3/30/09
|
InterMune to Present at Citi's 4th Annual Biotech Day
|
|
3/18/09
|
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
|
|
3/18/09
|
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
|
|
3/13/09
|
InterMune to Present at Cowen Health Care Conference
|
|
2/26/09
|
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
|
|
2/20/09
|
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
|
|
2/19/09
|
InterMune Announces Issuance of U.S. Patent for ITMN-191
|
|
2/13/09
|
InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
|
|
2/3/09
|
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
|
|
2/2/09
|
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
|
|
1/12/09
|
InterMune Reports Results from Triple Combination Study of ITMN-191
|
|
1/9/09
|
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
|
|
1/6/09
|
InterMune to Present at J.P. Morgan Healthcare Conference
|
|
12/10/08
|
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
|
|
11/14/08
|
InterMune to Present at Lazard Capital Markets Healthcare Conference
|
|
11/10/08
|
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
|
|
11/7/08
|
InterMune to Present at Deutsche Bank Biotech Boston Confab
|
|
11/6/08
|
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
|
|
10/28/08
|
InterMune to Release Third Quarter 2008 Financial Results on November 6
|
|
10/16/08
|
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
|
|
9/24/08
|
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
|
|
9/8/08
|
InterMune to Present at Baird Small Cap Healthcare Conference
|
|
9/2/08
|
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
|
|
8/29/08
|
InterMune to Present at Thomas Weisel Partners Healthcare Conference
|
|
8/7/08
|
InterMune to Present at Canaccord Adams Conference
|
|
7/30/08
|
InterMune to Present at BMO Healthcare Conference
|
|
7/24/08
|
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
|
|
6/20/08
|
InterMune to Present at Jefferies Healthcare Conference
|
|
6/6/08
|
InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
|
|
5/29/08
|
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
|
|
5/19/08
|
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
|
|
5/16/08
|
InterMune to Present at Citigroup Healthcare Conference
|
|
5/9/08
|
InterMune to Present at Bank of America Health Care Conference
|
|
5/1/08
|
InterMune Reports First Quarter 2008 Financial Results and Business Highlights
|
|
4/30/08
|
InterMune to Present at Deutsche Bank Health Care Conference
|
|
4/24/08
|
InterMune to Release First Quarter 2008 Financial Results on May 1
|
|
4/21/08
|
InterMune Announces Progress on Pirfenidone in IPF
|
|
4/2/08
|
InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
|
|
4/1/08
|
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
|
|
3/18/08
|
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
|
|
3/12/08
|
InterMune to Present at Cowen and Company and Lehman Brothers Health Care Conferences
|
|
2/28/08
|
InterMune to Present at the SIGnificant Options in Healthcare Conference
|
|
2/7/08
|
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
|
|
1/24/08
|
InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7
|
|
1/23/08
|
InterMune to Present at the 2008 Wachovia Healthcare Conference
|
|
1/7/08
|
InterMune Announces Continuing Progress on ITMN-191 (R7227)
|
|
1/2/08
|
InterMune to Present at the 26th Annual JPMorgan Healthcare Conference
|
|
11/26/07
|
InterMune Buys Out License Agreement for Pirfenidone
|
|
11/1/07
|
InterMune Announces Third Quarter 2007 Financial Results and Business Highlights
|
|
10/31/07
|
InterMune to Present at CIBC Healthcare Conference
|
|
10/22/07
|
InterMune to Release Third Quarter 2007 Financial Results on November 1
|
|
9/26/07
|
InterMune Announces Closing of Public Offering of Common Stock
|
|
9/26/07
|
InterMune Announces Start of Phase 1b Trial of ITMN-191
|
|
9/21/07
|
InterMune Announces Pricing of $68 Million Public Offering of Common Stock
|
|
2005
|
|
Date
|
Title
(click to view the full text) |
|
12/27/05
|
InterMune Announces Divestiture of Oritavancin
|
|
12/1/05
|
InterMune Elects David S. Kabakoff, Ph.D. To Board Of Directors
|
|
11/28/05
|
InterMune Sharpens Focus on Key Development Programs and Significantly Strengthens Financial Position
|
|
11/14/05
|
InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV
|
|
11/14/05
|
InterMune Presents HCV Protease Inhibitor Data at AASLD
|
|
11/9/05
|
InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
|
|
11/8/05
|
InterMune Announces Presentations at the 56th Annual Meeting of the American Association for the Study of Liver Diseases
|
|
11/1/05
|
InterMune Presents In Vitro Data at Annual Meeting of the American College of Chest Physicians
|
|
10/27/05
|
InterMune Announces Third Quarter Financial Results and Business Highlights
|
|
10/20/05
|
InterMune Announces Presentations at Annual Meeting of the American College of Chest Physicians
|
|
10/17/05
|
InterMune Provides Update on Its Two Phase III Pulmonology Programs
|
|
10/14/05
|
InterMune to Release Third Quarter Financial Results on October 27
|
|
9/21/05
|
InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
|
|
9/8/05
|
InterMune Announces Webcast of Corporate Presentation at the ThinkEquity Partners Growth Conference
|
|
9/7/05
|
Intermune Announces Issuance of Two Composition of Matter Patents for Actimmune(R)
|
|
7/28/05
|
InterMune Announces Second Quarter Financial Results
|
|
7/19/05
|
InterMune and Array BioPharma Expand Hepatitis C Drug Discovery Collaboration
|
|
7/12/05
|
InterMune to Release Second Quarter Financial Results on July 28
|
|
7/11/05
|
InterMune Completes Enrollment of the Phase III DIRECT Trial Evaluating Daily Infergen Plus Ribavirin in PEG-Nonresponders
|
|
6/2/05
|
InterMune Announces Webcast of Corporate Presentation at the Pacific Growth Equities Life Sciences Conference
|
|
5/24/05
|
InterMune Announces Divestiture of Amphotec
|
|
5/23/05
|
Data Presented at ATS 2005 Support Intermune's Current Phase III Trial Design Evaluating Actimmune(R) in IPF Patients
|
|
5/16/05
|
InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
|
|
5/16/05
|
InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders
|
|
5/16/05
|
InterMune Announces Presentation of Specificity and Tolerability Data for Two Novel Protease Inhibitor Drug Candidates
|
|
5/9/05
|
InterMune Reaches Preliminary Settlement Agreement for Shareholder Class Action Lawsuit
|
|
5/9/05
|
InterMune Announces Hepatitis C Presentations at Digestive Disease Week
|
|
5/9/05
|
InterMune Announces Presentations on Actimmune and IPF at ATS 2005
|
|
5/2/05
|
Promising Results From Phase II Study of Pirfenidone in IPF Patients
|
|
4/28/05
|
InterMune Announces First Quarter Financial Results
|
|
4/7/05
|
InterMune to Release First Quarter Financial Results on April 28
|
|
3/29/05
|
InterMune Provides an Update on Pirfenidone Development Plans
|
|
3/9/05
|
InterMune Announces Webcast of Corporate Presentation at the SG Cowen & Co. 25th Annual Health Care Conference
|
|
2/23/05
|
Intermune Announces Webcast of Corporate Presentation at the Wells Fargo 2005 Healthcare Conference
|
|
2/23/05
|
InterMune Announces Webcast of Corporate Presentation at the JMP Securities 4th Annual Research Conference
|
|
2/18/05
|
InterMune Announces Management Appointment
|
|
2/7/05
|
InterMune Announces Fourth Quarter and Year End Financial Results
|
|
1/25/05
|
InterMune to Release Fourth Quarter and Year-End 2004 Financial Results on February 7
|
|
1/10/05
|
InterMune Announces Webcast of Corporate Presentation at the JPMorgan Healthcare Conference
|
|
1/10/05
|
Largest Completed IPF Study Points to Survival as Key Endpoint in Future Actimmune Studies
|
